Lifecore Biomedical, Inc.

LFCR Healthcare Drug Manufacturers Specialty & Generic

Lifecore Biomedical, Inc.’s revenue for fiscal 2025 (year ended May 2025) was $128.9 million, roughly unchanged from fiscal 2024.

Revenue
−18.6%
EPS
−1,700.0%
Free cash flow
+27,684.0%
Total debt
+15.3%

Quarter to September 2026, against a year earlier

6.37 0.03 −0.47%
Market cap
$242.6M
P/E
0.0×
Fwd P/E
−6.4×
Dividend yield
—
F-score
3/9
Altman Z
0.12
Beneish M
−3.15
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Older periods Dec '25 Mar '26 Jun '26 Sep '26 From the 10-Q filed 4 Nov
Net Income

+8 more TTM periods

11.66 (24.97) (21.14) (51.23)
Operating Cash Flow
— 20.33 6.04 11.22
Investing cash flow
— (0.27) (4.55) —
Financing cash flow
— (9.86) 3.30 4.45
Ending Cash
— 53.09 46.69 —

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 4 Nov 2026